At the news
? NEUTRALIMPACT 6/10 8-K filed Nov 9, 2026 at 07:40 ET
Heron Therapeutics (HRTX) entered into a definitive asset purchase agreement to sell its commercial-stage anti-nausea and post-operative pain product portfolio (CINVANTI, SUSTOL, ZYNRELEF) to CorMedix Inc. (CRMD) for $145M in cash plus 14,583,333 CRMD shares, along with tiered royalty payments on CINVANTI/SUSTOL net sales above a $25M threshold and earn-out payments on ZYNRELEF up to $55M. Concurrently, Heron exchanged its $35M convertible notes held by Rubric Capital Management for a portion of the CRMD stock consideration, effectively deleveraging its balance sheet. The transaction requires Heron stockholder approval and is expected to close within six months.
- Heron sells its commercial product portfolio (CINVANTI, SUSTOL, ZYNRELEF) to CorMedix for $145M cash plus 14,583,333 CRMD shares (Stock Consideration).
- Heron exchanges its $35M convertible notes held by Rubric Capital Management for a portion of the CRMD stock consideration, eliminating that debt.
- Heron is eligible for 5% royalty payments on CINVANTI/SUSTOL net sales above a $25M annual threshold for calendar years 2027-2029.
- Heron is eligible for earn-out payments on ZYNRELEF: $25M if 2028 net sales reach $65M, plus $30M if they reach $95M (max $55M).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access